Prevention of postprandial hyperglycemia by acarbose may be a promising therapeutic strategy for reducing the increased risk for cardiovascular disease (ABDOMEN)
The use of acarbose in impaired glucose tolerance (IGT) and type 2 diabetic subjects has been associated with a significant reduction of cardiovascular events. Additionally, acarbose has been shown to have a beneficial influence on some of the other cardiovascular risk factors (metabolic syndrome components). Thus, prevention of postprandial hyperglycemia by acarbose may be a promising therapeutic strategy for reducing the increased risk for cardiovascular disease. Further studies are needed to confirm the influence of acarbose on cardiovascular risk factors in the real life setting.
- Diabetes Mellitus - Age >/= 18 years - Naive to acarbose (minimum 3 months before inclusion)
- Hypersensitivity to acarbose or any of the excipients - Age <18 years - Pregnancy and in nursing - Inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction - Chronic intestinal diseases associated with marked disorders of digestion or absorption - States which may deteriorate as a result of increased gas formation in the intestine, (e.g. Roemheld’s syndrome [an angina pectoris-like syndrome or aggravation of an angina pectoris due to the postprandial filling of the stomach] and larger hernias) - Hepatic and severe renal impairment (creatinine clearance <25 mL/min/ 1,73m2)
Many Locations, Poland
E-mail: [email protected]
Phone: Not Available
Acarbose in cardiovascular risk management. Assessment of clinical efficacy and safety of acarbose and its effect on selected cardiovascular risk factors in type 2 diabetes patients.